From the Eye Treatment Centre (Sanders, Lowin, Gupta, Roberts), West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, Department of Ophthalmology (Roberts), Ipswich Hospital, East Suffolk and North Essex NHS Foundation Trust, Ipswich, United Kingdom.
J Cataract Refract Surg. 2020 Jun;46(6):831-838. doi: 10.1097/j.jcrs.0000000000000192.
To assess the visual outcomes of pseudophakic cystoid macular edema (CME) as compared with age- and copathology-matched control subjects, the costs of treatment and follow-up, and the patient-reported outcomes using the new Cat-patient-reported outcome measures (PROM) 5 questionnaire.
West Suffolk Hospital NHS Foundation Trust, United Kingdom.
Matched case-control study.
Fifty-two eyes of 49 patients developed CME over an 18-month period. Age- and copathology-matched patients were identified from clinical records over the same time period in a 2:1 ratio (90 eyes). Postoperative clinical outcomes were recorded including treatments received, costs of treatments, and patient-reported outcome measures using the Cat-PROM5.
Patients with CME reported a significantly worse outcome from surgery than control subjects. Furthermore, patients with CME had significantly worse visual acuity postoperatively than control subjects (CME: logarithm of the minimum angle of resolution 0.40 ± 0.33, n = 37; control subjects: 0.30 ± 0.33; P < .05) despite there being no difference in preoperative visual acuity. In patients with epiretinal membrane (ERM), notably those with CME had worse patient-reported outcomes than control subjects with ERM, and only 18% received prophylactic corticosteroid injection at surgery compared with 63.6% of control subjects. CME resulted in an excess of 266 outpatient appointments, with 388 weeks of topical therapy, 18 orbital floor injections, 6 intravitreal steroid injections, 5 intravitreal antivascular endothelial growth factor injections, and 1 intravitreal dexamethasone implant with an excess expenditure of £216.81 per case.
Patients developing CME after cataract surgery had reduced visual acuity at 4 to 6 weeks, patient-reported visual outcomes, and increased number of hospital appointments, treatments, and costs.
与年龄和合并症相匹配的对照受试者相比，评估白内障术后囊样黄斑水肿（CME）的视力结果、治疗和随访的成本，以及使用新的 Cat-患者报告结果测量（PROM）5 问卷的患者报告结果。
英国萨福克郡西部医院 NHS 基金会信托。
匹配病例对照研究。
在 18 个月的时间内，49 名患者的 52 只眼发生了 CME。在同一时期内，从临床记录中以 2:1 的比例确定了年龄和合并症相匹配的患者（90 只眼）。记录术后临床结果，包括接受的治疗、治疗费用以及使用 Cat-PROM5 进行的患者报告结果测量。
与对照组相比，患有 CME 的患者报告术后手术结果明显更差。此外，与对照组相比，患有 CME 的患者术后视力明显更差（CME：最小角分辨率对数 0.40 ± 0.33，n = 37；对照组：0.30 ± 0.33；P <.05），尽管术前视力没有差异。在患有视网膜内膜（ERM）的患者中，特别是患有 CME 的患者，其患者报告结果明显比患有 ERM 的对照组差，只有 18%的患者在手术时接受了预防性皮质类固醇注射，而对照组为 63.6%。CME 导致额外增加了 266 次门诊预约，388 周局部治疗，18 次眶底注射，6 次眼内类固醇注射，5 次眼内抗血管内皮生长因子注射和 1 次眼内地塞米松植入，每个病例的额外支出为 216.81 英镑。
白内障手术后发生 CME 的患者在 4 至 6 周时视力下降，患者报告的视觉结果以及就诊次数、治疗和费用增加。
